Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $36.50

Pacira BioSciences (NASDAQ:PCRX) had its price target raised by analysts at Royal Bank Of Canada from $25.00 to $36.50 in a research note issued on Friday, Benzinga reports. The brokerage currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s target price points to a potential upside of 0.48% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. Zacks Research downgraded shares of Pacira BioSciences from a “hold” rating to a “strong sell” rating in a research note on Monday. Leerink Partners began coverage on shares of Pacira BioSciences in a research note on Wednesday, September 9th. They set a “market perform” rating and a $28.00 target price on the stock. Needham & Company LLC downgraded shares of Pacira BioSciences from a “buy” rating to a “hold” rating in a research report on Thursday. JPMorgan Chase & Co. raised Pacira BioSciences from an “underweight” rating to a “neutral” rating and set a $36.50 price target for the company in a report on Thursday. Finally, Jefferies Financial Group restated a “hold” rating and issued a $36.00 price target on shares of Pacira BioSciences in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $32.72.

Pacira BioSciences Price Performance

Shares of Pacira BioSciences stock traded down $0.07 on Friday, reaching $36.33. The stock had a trading volume of 1,466,777 shares, compared to its average volume of 815,018. Pacira BioSciences has a 1 year low of $18.80 and a 1 year high of $36.46. The company has a current ratio of 5.04, a quick ratio of 3.94 and a debt-to-equity ratio of 0.54. The company has a market cap of $1.45 billion, a P/E ratio of 103.79 and a beta of 0.25. The business’s 50 day moving average is $25.37 and its two-hundred day moving average is $24.51.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. The company had revenue of $192.40 million during the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $0.74 earnings per share. As a group, research analysts anticipate that Pacira BioSciences will post 1.91 EPS for the current year.

Insider Activity

In other news, insider Jonathan Slonin sold 3,040 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $23.23, for a total transaction of $70,619.20. Following the completion of the sale, the insider owned 216,384 shares in the company, valued at approximately $5,026,600.32. This represents a 1.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in PCRX. Bank of New York Mellon Corp acquired a new stake in shares of Pacira BioSciences in the second quarter worth $7,532,000. Bank of America Corp DE purchased a new stake in Pacira BioSciences in the 2nd quarter valued at $6,089,000. Empowered Funds LLC acquired a new position in Pacira BioSciences in the second quarter valued at approximately $5,076,000. PDT Partners LLC acquired a new position in shares of Pacira BioSciences in the second quarter valued at approximately $3,358,000. Finally, Man Group plc acquired a new position in shares of Pacira BioSciences during the second quarter worth about $3,181,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences News Roundup

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris acquisition provides a clear cash exit. Viatris will acquire Pacira for $36.50 per share in cash, valuing the equity at approximately $1.65 billion. The transaction gives shareholders near-term deal certainty and values Pacira’s EXPAREL and ZILRETTA non-opioid pain medicines as strategic additions to Viatris’ portfolio. Closing is expected by the end of 2026. Viatris Agrees to Acquire Pacira BioSciences
• Positive Sentiment: Deal news triggered substantial buying. Reports indicated PCRX jumped about 44% and reached a 52-week high as investors repriced the shares toward Viatris’ $36.50 offer. Pacira BioSciences jumps on Viatris acquisition deal
• Neutral Sentiment: Analyst targets now largely reflect the transaction price. JPMorgan upgraded Pacira from underweight to neutral with a $36.50 target, while HC Wainwright reaffirmed neutral but reduced its target from $38 to $36.50. Jefferies maintained hold with a $36 target, and Needham cut its rating from buy to hold. These actions suggest limited fundamental upside beyond the proposed cash consideration.
• Neutral Sentiment: Truist raised its target to $31 and retained a buy rating, but the target is now below the current deal-related valuation. Pacira receives price target increase from Truist Financial
• Negative Sentiment: Shareholder law firms are investigating the transaction. Several firms are questioning whether the $36.50 offer fairly values Pacira, whether the board conducted an adequate sale process, and whether insiders received improper benefits. Such reviews could create legal or closing uncertainty, although they do not currently change the announced offer.
• Negative Sentiment: Bearish options activity was also reported in PCRX, signaling some traders are positioning for limited downside or deal-related uncertainty. Stocks drawing bearish options activity

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.